Inward Investment

Inward Investment News

View news from other Pharmaceutical sectors:
106-120 of 421 results
Bristol-Myers Squibb to take over Amylin pharmaceuticals
By PBR Staff Writer
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn.
Inward Investment > News
Cornerstone buys EKR Therapeutics
By PBR Staff Writer
Cornerstone Therapeutics has acquired a privately-held specialty pharmaceutical company focused on the acute-care hospital setting, EKR Therapeutics.
Inward Investment > News
InterMune completes sale of Actimmune
By PBR Staff Writer
InterMune has completed divestiture of Actimmune (interferon gamma-1b) to Vidara Therapeutics, a part of an international specialty pharmaceutical group of companies with operations in Ireland and the US.
Inward Investment > News
AstraZeneca takes over Ardea Biosciences
By PBR Staff Writer
AstraZeneca, a biopharmaceutical company, has completed the purchase of a US-based biotechnology company, Ardea Biosciences.
Inward Investment > News
Valeant Pharmaceuticals to acquire OraPharma
By PBR Staff Writer
Valeant Pharmaceuticals has signed an agreement to buy OraPharma, an oral health company, from Water Street Healthcare Partners.
Inward Investment > News
Amgen takes over more than 99% of MN Pharmaceuticals shares
By PBR Staff Writer
Amgen has completed the acquisition of more than 99% of the shares of Mustafa Nevzat Pharmaceuticals (MN Pharmaceuticals), a privately held Turkish company.
Inward Investment > News
Takeda America takes over URL Pharma
By PBR Staff Writer
Takeda America Holdings, a wholly owned subsidiary of Takeda Pharmaceutical Company, has acquired URL Pharma for an upfront payment of $800m.
Inward Investment > News
Eli Lilly opens new diabetes-focused R&D center in China
By PBR Staff Writer
Eli Lilly and Company has officially opened the Lilly China Research and Development Center (LCRDC), a diabetes-focused research and development center in Shanghai, China.
Inward Investment > News
InterMune signs deal with Vidara Therapeutics to divest Actimmune
By PBR Staff Writer
InterMune has signed a definitive agreement with Vidara Therapeutics International (Vidara) to sell its rights to Actimmune (interferon gamma-1b) in $55m cash transaction and a two-year royalty stream.
Inward Investment > News
Piramal Healthcare to take over DRG
By PBR Staff Writer
Indian drug maker Piramal Healthcare has decided to acquire US-based healthcare data provider, Decision Resources Group (DRG), for a consideration of around $635m.
Inward Investment > News
Unipex Group takes over Debro Pharma
By PBR Staff Writer
Unipex Group, through its wholly owned Canadian subsidiary, Unipex Solutions Canada, has acquired Debro Pharma from Debro Chemicals.
Inward Investment > News
Abbott to obtain AP214 rights from Action Pharma
By PBR Staff Writer
Abbott has signed an agreement to acquire all global rights to develop and commercialize AP214 from Action Pharma.
Inward Investment > News
AstraZeneca, Ardea Biosciences sign definitive merger agreement
By PBR Staff Writer
AstraZeneca and Ardea Biosciences have entered into a definitive merger agreement, under which AstraZeneca will acquire Ardea for $1.26bn including a product lesinurad in Phase III development for gout.
Inward Investment > News
BioTime, LifeMap to take over XenneX
By PBR Staff Writer
BioTime and its wholly owned subsidiary, LifeMap Sciences, have announced an agreement to purchase XenneX.
Inward Investment > News
HGS rejects $2.6bn takeover bid by GSK
By PBR Staff Writer
Human Genome Sciences (HGS) has rejected $2.6bn (£1.6bn) takeover bid offered by GlaxoSmithKline (GSK).
Inward Investment > News
106-120 of 421 results